Immunic, Inc. (IMUX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Duane D. Nash J.D., M.B.A., M.D. | Executive Chairman | 504.57k | -- | 1971 |
| Dr. Daniel Vitt Ph.D. | CEO & Director | 869.96k | -- | 1968 |
| Dr. Andreas Muehler M.D., Ph.D. | Chief Medical Officer | 694.86k | -- | 1965 |
| Mr. Jason Tardio M.B.A. | COO & President | 360k | -- | 1978 |
| Dr. Hella Kohlhof | Chief Scientific Officer | -- | -- | 1974 |
| Ms. Jessica Breu | Head of Investor Relations & Communications | -- | -- | -- |
| Mr. Inderpal Singh | General Counsel | -- | -- | 1967 |
| Mr. Patrick Walsh | Chief Business Officer | -- | -- | 1984 |
Immunic, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 91
Description
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
May 6, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Immunic, Inc. Earnings Date